Edition note: An independent English rewriting for readers of Dying to Survive. It preserves the Chinese argument while reorganizing its sequence for an English-language essay. Full-film spoilers.

Every Rule Has a Reason

Cheng Yong runs a failing shop that sells Indian aphrodisiacs. A man wearing three surgical masks walks in and asks for something else: can Cheng bring a leukemia drug back from India?

The medicine sold legally in China costs tens of thousands of yuan a bottle. The Indian generic costs hundreds at its source. For a patient with chronic myeloid leukemia, this is not a comparison between a luxury brand and a bargain. It is the difference between continuing treatment and watching a family's savings disappear month by month.

A price is built from more than greed

Dying to Survive could have made the pharmaceutical company a simple villain. Instead, even its corporate representative is given a defensible argument: developing a successful drug requires years of research, large investment, and many failures. Patent protection gives an innovator a period in which competitors cannot simply reproduce the result. Without some prospect of return, the next treatment may never be funded.

This does not prove that any particular price is just. Research costs, monopoly power, marketing, public subsidies, insurance bargaining, and global income differences all enter the eventual number. “Innovation needs reward” is a reason for a rule, not a blank check for every outcome.

The generic is not costless either. Manufacturers still need reliable production, testing, and distribution. What they do not carry in the same way is the originator's discovery risk—and in the film, that difference produces a radically lower price.

“Fake” in law and “fake” in chemistry

The film's legal setting also needs precision. At the time, Chinese drug law treated a medicine that required approval but was imported without it as a “fake drug” for legal purposes. That classification did not necessarily mean the pills lacked the active ingredient. It meant they had entered the market outside the domestic approval system.

Approval has an indispensable purpose. Patients cannot personally inspect a factory, verify purity, or evaluate clinical evidence. Regulation substitutes public scrutiny for trust in an unknown seller. The film includes an actual fraudster precisely to show what happens when desperation becomes a market.

Yet the same system can produce a cruel result. A drug may be effective and lawfully manufactured abroad while remaining illegal to sell domestically. The person who brings it to patients can be prosecuted under rules designed to protect those patients.

No single villain solves the problem

Patent incentives, drug approval, criminal enforcement, and patient safety each have a reason. Saying so does not require declaring every detail correct. It reveals the film's harder problem: institutions can pursue legitimate goods one by one and still leave a group of people with no livable option.

The company protects an invention. Regulators protect the drug supply. Police enforce the law. None of these descriptions contains the patient who has sold a home to buy another month's survival.

An elderly woman tells the investigating officer what that omission feels like. She has taken the expensive medicine for years and consumed her family's assets along with it. She does not offer a patent theory or a regulatory alternative. She says that the cheap medicine has kept her alive. Then she asks whether anyone can promise never to become ill.

Her speech brings a fact into the room that every institutional rule has translated into something else: a market demand, a safety risk, an illegal transaction, a case number. She restores the first-person sentence beneath those categories—I do not want to die.

When protection excludes the protected

The problem is not that rules exist. Nor is it solved by pretending unapproved supply chains are safe. The problem appears when a system can explain the purpose of every boundary but offers no answer to the people whose lives remain outside all of them.

A regulation earns trust not only by naming what it prevents, but by remaining answerable to those who cannot survive its result. That may require insurance coverage, price negotiation, accelerated review, lawful generic competition, patient assistance, or exceptions shaped carefully enough not to create a new market for fraud.

The film does not design that policy. It holds the gap open long enough for viewers to see the people inside it.

The next essay follows Cheng into that gap. The first time he enters, he is not a hero. He needs money.